OUR STORY
2013 – First POC for wound healing
UCB-MNC-derived EV are shown to accelerate wound healing in vivo, in healthy and diabetic animals
2014 – UCB-MNC-EV demonstrated to be superior to platelet-derived growth factor BB.
Possible mechanism of action uncovered.
2014 – Exogenus’ founders participate in a technology commercialization acceleration program
2015 – Provisional patent submitted to USPTO
2015 – Exogenus Therapeutics was founded by Joana Correia, Luísa Marques and Ricardo Neves, as a result of winning COHiTEC.
2015 – Newly-founded Exogenus Therapeutics secured €100K in pre-seed investment
2015 – Exclusive licensing of patent WO/2017/163132 to Exogenus Therapeutics
2015 – Exogenus Therapeutics is awarded ANJE‘s Young Entrepreneur Award
2015 – Exogenus Therapeutics secures €800K in seed funding.
2016 – Development of an optimized, GMP-compliant and scalable method for the production of umbilical cord-blood derived EV (Exo-101)
2016 – Exogenus Therapeutics is selected to receive support from Horizon 2020’s SME Instrument Phase 1
2016 – Exogenus Therapeutics awarded with the Everis Foundation award
2017 – Exogenus Therapeutics recognized at BioEurope, in Berlin
2018 – Development of a poloxamer-based hydrogel for Exo-101 delivery in wounds
2018 – Filing of international patent PCT/IB2019/058462: Compositions Comprising Small Extracellular Vesicles Derived From Umbilical Cord Blood Mononuclear Cells With Anti-Inflammatory And Immunomodulatory Propertiess
2018 – Exogenus Therapeutics is selected as one of the top 500 Deep Tech Startups of Hello Tomorrow
2019 – Exogenus Therapeutics awarded the Prémio Empreendedor XXI 2018
2019 – Exogenus Therapeutics secures funding under Horizon 2020 INNOSUP
2020 – Exogenus Therapeutics selected to participate in Novartis SciCare Accelerator Program
021 – Patent rights granted in Japan
2021 –Publication of non-GLP study results concerning Exo-101’s safety and biodistribution in rats
2021 – Publication of Exo-101’s effect in inflammation and skin diseases
2021 – Exogenus awarded at the Go Global Awards
2022 – Patent rights granted in China and Korea
2022 – Patent submission concerning the use of Exo-101 in fibrotic disorders
2022 – Collaborative R&D project for gene delivery using EV-associated AAV
2023 – Collaborative R&D project with global pharmaceutical company to explore drug’s MoA
2023 – Patent rights granted in Canada
2024 – Exogenus secures funding by 3XP Global to accelerate pipeline development